Hepatitis C Measures Group

This measures group is to be reported for patients aged 18 years and older with a specific diagnosis of chronic hepatitis C receiving office or other outpatient services (for new and established patient). Some measures in the Hepatitis C Measures Group apply only to a subset of these patients (eg, measure applies to female patients aged 18 through 44 years and all men aged 18 years and older)

You will need to report G-Code G8545 once to indicate your intent to report on the Hepatitis C Measures Group. Once you have reported the G-Code, you should begin reporting using one of the patient sample methods listed below.

The following 2011 Physician Quality Reporting System measures are included in the Hepatitis C Measures Group:

#84. Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment

Measure Description

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative HCV RNA testing was performed within 6 months prior to initiation of antiviral treatment

#85. Hepatitis C: HCV Genotype Testing Prior to Treatment

Measure Description

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom HCV genotype testing was performed prior to initiation of antiviral treatment

#86. Hepatitis C: Antiviral Treatment Prescribed Measure Description

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who were prescribed peginterferon and ribavirin therapy within the 12-month reporting period

#87. Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment

Measure Description

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative HCV RNA testing was performed at 12 weeks from the initiation of antiviral treatment

#89. Hepatitis C: Counseling Regarding Risk of Alcohol Consumption

Measure Description

Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who were counseled about the risks of alcohol use at least once within 12-months.

#90. Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy

Measure Description

Percentage of female patients aged 18 through 44 years and all men aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment who were counseled regarding contraception prior to the initiation of treatment

#183. Hepatitis C: Hepatitis A Vaccination in Patients with HCV

Measure Description

Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who received at least one injection of hepatitis A vaccine, or who have documented immunity to hepatitis A

#184. Hepatitis C: Hepatitis B Vaccination in Patients with HCV

Measure Description

Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who received at least one injection of hepatitis B vaccine, or who have documented immunity to hepatitis B

This measures group can be reported by one of the following patient sample methods:

- 30 Patient Sample Method 30 unique Medicare Part B FFS (fee for service) patients meeting patient sample criteria for the measures group.
- Sample Method via Reigstry All patients meeting patient sample criteria for the measure group during the entire reporting period (January 1 through December 31, 2011 OR July 1 through December 31, 2011). For the 12-month reporting period, a minimum of 15 Medicare Part B FFS patients must meet the measures group patient sample criteria to report satisfactory. For the 6-month reporting period, a minimum of 8 Medicare Part B FFS patients must meet the measures group patient sample criteria to report satisfactory.

continued on next page

Hepatitis C Measures Group

continued from previous page

Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement® (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

© 2007 American Medical Association. All Rights Reserved

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT**) or other coding contained in the specifications.

THE SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND

CPT® contained in the Measures specifications is copyright 2010 American Medical Association.

Physician Quality Reporting System 2011 Hepatitis C Measures Group, Effective Date 01/01/2011 © 2007 American Medical Association. All rights reserved.